
Daniel A Rodrigues

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1388544/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?. Journal of Medicinal Chemistry, 2018, 61, 5805-5821.	6.4	343
2	N-Acylhydrazones as drugs. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2797-2806.	2.2	140
3	Design, Synthesis, and Pharmacological Evaluation of Novel <i>N</i> -Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 655-670.	6.4	86
4	Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases. Pharmaceuticals, 2019, 12, 69.	3.8	53
5	Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities. Medicinal Research Reviews, 2020, 40, 2177-2211.	10.5	38
6	Synthesis, characterization, DNA binding, DNA cleavage, protein binding and cytotoxic activities of Ru(II) complexes. International Journal of Biological Macromolecules, 2016, 82, 663-670.	7.5	33
7	Design, Synthesis, and Pharmacological Evaluation of Firstâ€inâ€Class Multitarget <i>N</i> â€Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors. ChemMedChem, 2020, 15, 539-551.	3.2	28
8	The Use of Conformational Restriction in Medicinal Chemistry. Current Topics in Medicinal Chemistry, 2019, 19, 1712-1733.	2.1	26
9	Beyond the Selective Inhibition of Histone Deacetylase 6. Mini-Reviews in Medicinal Chemistry, 2016, 16, 1175-1184.	2.4	17
10	Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositolâ€3â€kinase (PI3K): Current and Future Prospects. ChemMedChem, 2021, 16, 448-457.	3.2	16
11	Theoretical and experimental characterization of 1,4-N⋯S σ-hole intramolecular interactions in bioactive <i>N</i> -acylhydrazone derivatives. New Journal of Chemistry, 2018, 42, 497-505.	2.8	15
12	Biotransformation of LASSBio-579 and pharmacological evaluation of p -hydroxylated metabolite a N -phenylpiperazine antipsychotic lead compound. European Journal of Medicinal Chemistry, 2013, 62, 214-221.	5.5	14
13	Recent Advances in Development of Polyphenols as Anticancer Agents. Mini-Reviews in Medicinal Chemistry, 2018, 18, 1265-1269.	2.4	13
14	An Unusual Intramolecular Halogen Bond Guides Conformational Selection. Angewandte Chemie - International Edition, 2018, 57, 9970-9975.	13.8	12
15	Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPR40). Chemical Biology and Drug Design, 2018, 91, 668-680.	3.2	11
16	Advances in the Design and Development of PROTAC-mediated HDAC Degradation. Current Topics in Medicinal Chemistry, 2022, 22, 408-424.	2.1	10
17	Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer. Pharmaceuticals, 2021, 14, 387.	3.8	8
18	Modeling zincâ€oxygen coordination in histone deacetylase: A comparison of semiempirical methods performance. International Journal of Quantum Chemistry, 2018, 118, e25720.	2.0	5

#	Article	IF	CITATIONS
19	Structure–property relationship studies of 3-acyl-substituted furans: the serendipitous identification and characterization of a new non-classical hydrogen bond donor moiety. New Journal of Chemistry, 2020, 44, 10994-11005.	2.8	3
20	Design, synthesis, structural characterization and in vitro cytotoxic activity of mononuclear Ru(II)complexes. Medicinal Chemistry Research, 2016, 25, 2127-2132.	2.4	1
21	Recent Advances in the Use of Multitarget Therapeutics. Current Topics in Medicinal Chemistry, 2022, 22, 331-332.	2.1	Ο